TY - JOUR
T1 - Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
AU - Dang, Chau
AU - D'Andrea, Gabriella
AU - Lake, Diana
AU - Sugarman, Steve
AU - Fornier, Monica
AU - Moynahan, Mary Ellen
AU - Gilewski, Theresa
AU - Hurria, Arti
AU - Mills, Nancy
AU - Troso-Sandoval, Tiffany
AU - George, Roshini
AU - Robson, Mark
AU - Dickler, Maura
AU - Smith, Karen
AU - Panageas, Katherine
AU - Norton, Larry
AU - Hudis, Clifford
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2008/10/1
Y1 - 2008/10/1
N2 - Purpose: We conducted a pilot study of dose-dense epirubicin/ cyclophosphamide (EC) × 6 → paclitaxel (P) × 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) × 6 with filgrastim → by weekly paclitaxel alternating with docetaxel × 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase). Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility. Patients and Methods: Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal status. Treatment regimen consisted of every-2-week EC (100/600 mg/m2) × 6 → by 2-weekly P (175 mg/m2) × 6 with pegfilgrastim 6 mg on day 2. Results: Between November 2004 and May 2005, 38 patients were enrolled. The median age was 47 years (range, 30-72 years); 33 of 38 (87%) were treated in the adjuvant setting and 27 of 33 (81%) had involved nodes (range, 1-46); 5 of 38 (13%) were treated pre-operatively; 33 of 38 (87%) completed all chemotherapy as planned; the remaining patients (13%) had treatment modifications for toxicity. Febrile neutropenia occurred in 6 of 38 patients (16 %) and only during EC. There were 12 hospitalizations in 9 of 38 patients (24%) enrolled. Conclusion: Dose-dense every-2-week EC × 6 → P × 6 with pegfilgrastim is feasible based on our prospective definition.
AB - Purpose: We conducted a pilot study of dose-dense epirubicin/ cyclophosphamide (EC) × 6 → paclitaxel (P) × 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) × 6 with filgrastim → by weekly paclitaxel alternating with docetaxel × 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase). Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility. Patients and Methods: Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal status. Treatment regimen consisted of every-2-week EC (100/600 mg/m2) × 6 → by 2-weekly P (175 mg/m2) × 6 with pegfilgrastim 6 mg on day 2. Results: Between November 2004 and May 2005, 38 patients were enrolled. The median age was 47 years (range, 30-72 years); 33 of 38 (87%) were treated in the adjuvant setting and 27 of 33 (81%) had involved nodes (range, 1-46); 5 of 38 (13%) were treated pre-operatively; 33 of 38 (87%) completed all chemotherapy as planned; the remaining patients (13%) had treatment modifications for toxicity. Febrile neutropenia occurred in 6 of 38 patients (16 %) and only during EC. There were 12 hospitalizations in 9 of 38 patients (24%) enrolled. Conclusion: Dose-dense every-2-week EC × 6 → P × 6 with pegfilgrastim is feasible based on our prospective definition.
KW - Adjuvant chemotherapy
KW - Pegfilgrastim
UR - http://www.scopus.com/inward/record.url?scp=58149242954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149242954&partnerID=8YFLogxK
U2 - 10.3816/CBC.2008.n.050
DO - 10.3816/CBC.2008.n.050
M3 - Article
C2 - 18952555
AN - SCOPUS:58149242954
SN - 1526-8209
VL - 8
SP - 418
EP - 424
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 5
ER -